Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized...

Integrating bioinformatics strategies in cancer immunotherapy: current and future perspectives

HN Washah, EY Salifu, O Soremekun… - … Chemistry & High …, 2020 - ingentaconnect.com
For the past few decades, the mechanisms of immune responses to cancer have been
exploited extensively and significant attention has been given into utilizing the therapeutic …
被引用次数：8 相关文章 所有 3 个版本

Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity

Y Xu, Y Xiao, C Luo, Q Liu, A Wei, Y Yang… - International …, 2020 - Elsevier
Antibody therapy based on PD-1/PD-L1 blocking or ADCC effector has produced significant
clinical benefit for cancer patients. We generated a novel anti-B7-H3 antibody (07B) and …
被引用次数：15 相关文章 所有 4 个版本